Swiss pharmaceutical supplier Skan Group reported a significant increase in both sales and profit, driven by a reduction in project postponements.
The Basel-land-based company stated that fewer delays in ongoing projects allowed for smoother operational execution and revenue recognition. Following the positive financial results, Skan confirmed its previously issued business outlook.
